January 14, 2026 – Talk Bio

Actionable Insights Powered by AI

FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels

13 hours ago talkbio0Tagged eli lilly, Glucagon-Like Peptide 1, Saxenda, suicide warnings, United States Food and Drug Administration, Wegovy, Zepbound

FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda

Bristol Myers Squibb Completes $4.8 Billion Acquisition of Mirati Therapeutics

14 hours ago talkbio0Tagged Acquisition, KRAS NP_004976.2:p.G12C, Myers Squibb, Neoplasms

Bristol Myers Squibb; Mirati Therapeutics; acquisition; $4.8 billion; KRAZATI; oncology; KRAS G12C

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

15 hours ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, JPM26, Mike Doustdar, Novo Nordisk, Obesity, semaglutide, Wegovy pill

Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide

JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments

17 hours ago talkbio0Tagged eli lilly, JPM26, JPMHC, Novo Nordisk, oral obesity drugs, orglipron, semaglutide

Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide

Lightning Step and Sunwave Achieve SOC 2 Type II Attestation, Strengthening Security and Trust Across Healthcare Technology

1 day ago talkbio0Tagged Biomechanical compliance, Healthcare technology, Lightning Step, Security - service, spindle orientation checkpoint, Sunwave, Type 2

Lightning Step; Sunwave; SOC 2 Type II; Healthcare Technology; Security; Compliance